Transcode Therapeutics Inc
RNAZ0.564USD
+0.157+38.71%
Close 05/01, 16:00（ET）Quotes delayed by 15 min
580.41KMarket Cap
LossP/E TTM
More Details of Transcode Therapeutics Inc Company
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. The Company is focused on treating cancer through the design and delivery of ribonucleic acid (RNA) therapeutics based on its TTX nanoparticle platform. The Company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 (PD-L1), and two indication agnostic programs, TTX-RIGA, an RNA-based agonist of the retinoic acid- inducible gene I (RIG-I), targeting activation of innate immunity in the tumor microenvironment; and TTX- CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells. The Company’s pipeline also includes TTX-mRNA, a tumor-type specific mRNA-based platform for the development of cancer vaccines.
Company Info
Company codeRNAZ
Company nameTranscode Therapeutics Inc
IPO dateApr 28, 2021
Founded at2016
CEOMr. Thomas A. Fitzgerald
Number of employees7
Security typeOrdinary Share
Fiscal year-endApr 28
Address6 Liberty Square
CityBOSTON
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code02109
Phone18573016857
Websitehttps://www.transcodetherapeutics.com/
Company codeRNAZ
IPO dateApr 28, 2021
Founded at2016
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas A. Fitzgerald
Mr. Thomas A. Fitzgerald
Interim Chief Executive Officer, Chief Financial Officer, Vice President, Director
Interim Chief Executive Officer, Chief Financial Officer, Vice President, Director
43.00
--
Dr. Philippe P. Calais, Ph.D.
Dr. Philippe P. Calais, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.00
--
Dr. Erik Manting, Ph.D.
Dr. Erik Manting, Ph.D.
Independent Director
Independent Director
--
--
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
--
--
Dr. Daniel Vlock
Dr. Daniel Vlock
Chief Medical Officer
Chief Medical Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas A. Fitzgerald
Mr. Thomas A. Fitzgerald
Interim Chief Executive Officer, Chief Financial Officer, Vice President, Director
Interim Chief Executive Officer, Chief Financial Officer, Vice President, Director
43.00
--
Dr. Philippe P. Calais, Ph.D.
Dr. Philippe P. Calais, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.00
--
Dr. Erik Manting, Ph.D.
Dr. Erik Manting, Ph.D.
Independent Director
Independent Director
--
--
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
--
--
Dr. Daniel Vlock
Dr. Daniel Vlock
Chief Medical Officer
Chief Medical Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholder
Update time: Fri, Apr 18
Update time: Fri, Apr 18
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
Sabby Management, LLC
0.30%
Tracy (Thomas Joseph)
0.15%
Bigger Capital Funds, LP
0.15%
District 2 Capital LP
0.15%
The Vanguard Group, Inc.
0.04%
Other
99.22%
Shareholder Statistics
Shareholder
Proportion
Sabby Management, LLC
0.30%
Tracy (Thomas Joseph)
0.15%
Bigger Capital Funds, LP
0.15%
District 2 Capital LP
0.15%
The Vanguard Group, Inc.
0.04%
Other
99.22%
Type
Shareholder
Proportion
Investment Advisor/Hedge Fund
0.34%
Hedge Fund
0.33%
Individual Investor
0.15%
Investment Advisor
0.04%
Other
99.14%
Institutional Shareholding
Update time: Tue, Mar 4
Update time: Tue, Mar 4
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
35
200.14K
0.86%
+178.23K
2024Q4
36
155.76K
22.37%
+143.23K
2024Q3
40
10.06K
1.97%
-8.53K
2024Q2
41
8.22K
4.45%
-5.03K
2024Q1
41
12.92K
7.67%
+11.92K
2023Q4
41
826.00
4.24%
+40.00
2023Q3
39
727.00
50.61%
+276.00
2023Q2
40
361.00
37.13%
+105.00
2023Q1
39
172.00
28.71%
-82.00
2022Q4
37
893.26K
29.27%
+893.01K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Sabby Management, LLC
69.56K
0.3%
+69.56K
--
Dec 31, 2024
Tracy (Thomas Joseph)
35.00K
0.15%
+35.00K
--
Mar 07, 2025
Bigger Capital Funds, LP
34.55K
0.15%
+34.55K
--
Dec 17, 2024
District 2 Capital LP
34.55K
0.15%
+34.55K
--
Dec 17, 2024
UBS Financial Services, Inc.
8.68K
0.04%
+8.68K
--
Dec 31, 2024
Anson Funds Management LP.
6.64K
0.03%
+6.64K
--
Dec 31, 2024
Tower Research Capital LLC
926.00
0%
+730.00
+372.45%
Dec 31, 2024
CAPTRUST Financial Advisors
492.00
0%
+151.00
+44.28%
Sep 30, 2024
Morgan Stanley Smith Barney LLC
303.00
0%
--
--
Dec 31, 2024
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Nov 25, 2024
Merger
33<1
Nov 25, 2024
Merger
33<1
Nov 25, 2024
Merger
33<1
Nov 25, 2024
Merger
33<1
Jan 11, 2024
Merger
40<1
Jan 11, 2024
Merger
40<1
Date
Type
Ratio
Nov 25, 2024
Merger
33<1
Nov 25, 2024
Merger
33<1
Nov 25, 2024
Merger
33<1
Nov 25, 2024
Merger
33<1
Jan 11, 2024
Merger
40<1
Jan 11, 2024
Merger
40<1
Jan 11, 2024
Merger
40<1
Jan 11, 2024
Merger
40<1
May 22, 2023
Merger
20<1
May 22, 2023
Merger
20<1
View more